Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
NasdaqCM - Delayed Quote USD

SciSparc Ltd. (SPRC)

Compare
0.3040
+0.0171
+(5.96%)
At close: April 2 at 4:00:00 PM EDT
0.3000
-0.00
(-1.32%)
After hours: April 2 at 6:58:27 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for SPRC

Recent News: SPRC

View More
SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea

SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea
GlobeNewswire 23 days ago
Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea

Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea
GlobeNewswire 23 days ago
SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers

SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers
GlobeNewswire 30 days ago
SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax’s Entry into Direct Import of JAC Electric Vehicles

SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax’s Entry into Direct Import of JAC Electric Vehicles
GlobeNewswire last month
N2OFF Signs Definitive Agreement to Acquire Next-Gen Computational Drug Discovery Company, Targeting Hard To Treat Cancers

N2OFF Signs Definitive Agreement to Acquire Next-Gen Computational Drug Discovery Company, Targeting Hard To Treat Cancers
GlobeNewswire last month
SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology

SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology
GlobeNewswire last month
SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico

SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico
GlobeNewswire last month
SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
GlobeNewswire 2 months ago
SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles

SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles
GlobeNewswire 2 months ago
SciSparc says MitoCareX expands research to pancreatic cancer

SciSparc says MitoCareX expands research to pancreatic cancer
TipRanks 2 months ago
SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results

SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results
GlobeNewswire 2 months ago
View More

Related Tickers

ZVSA ZyVersa Therapeutics, Inc.
0.5873
-0.03%
 
PXMD PaxMedica, Inc.
0.0002
0.00%
 
ENSC Ensysce Biosciences, Inc.
2.6400
+5.60%
 
CMND Clearmind Medicine Inc.
1.0300
0.00%
 
CDIO Cardio Diagnostics Holdings, Inc.
0.3449
-4.19%
 
QNRX Quoin Pharmaceuticals, Ltd.
0.2925
+37.52%
 
VRAX Virax Biolabs Group Limited
1.1400
+5.56%
 
KTTA Pasithea Therapeutics Corp.
1.1900
-4.03%
 
PALI Palisade Bio, Inc.
0.6676
-0.33%
 
TVGN Tevogen Bio Holdings Inc.
1.0700
-1.83%